Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.30 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.30 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12848460 | 0.87 | GPR142 (0.37) | MAPTALDH1A1STIM1ORAI1 | |
| SCHEMBL12848568 | 0.87 | MAPT (0.34) | MAPTALDH1A1SMN1; SMN2STIM1ORAI1 | |
| SCHEMBL12848966 | 0.86 | MAPT (0.33) | MAPTALDH1A1STIM1ORAI1DHODH | |
| SCHEMBL12848567 | 0.86 | MAP3K5 (0.39) | — | |
| SCHEMBL12848915 | 0.85 | MAPT (0.36) | MAPTALDH1A1LMNASMN1; SMN2STIM1 | |
| SCHEMBL12848749 | 0.85 | MAPT (0.34) | MAPTALDH1A1STIM1ORAI1DHODH | |
| SCHEMBL12848856 | 0.85 | MAPT (0.33) | MAPTALDH1A1STIM1ORAI1DHODH | |
| SCHEMBL12848566 | 0.85 | MAP3K5 (0.35) | MAPTALDH1A1STIM1ORAI1DHODH | |
| SCHEMBL12848854 | 0.85 | MAPT (0.34) | MAPTSTIM1ORAI1DHODH | |
| SCHEMBL12848964 | 0.83 | MAPT (0.33) | MAPTSTIM1ORAI1DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | TSLP, NFATC1, IL5 | HTR2A 3969/4885HTR2C 4033/4885HTR2B 3769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.